Clinical trials: Ovarian
Ovarian Cancer
Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
Poly(ADP-ribose) polymerase (PARP) inhibitors are anti-cancer treatments that induce preferential tumor cell death. Their efficacy has been demonstrated in many tumor models, primarily in advanced ovarian cancer.
- Trial name
- PARIB-OLD-PRO² (NCT06572735)
- Testing
- QoL surveys, Geriatric assessment (G-CODE), Blood sampling
- Where
- 16 sites in France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Blood Pressure, Hypertension
Onco-primary Care Networking to Support TEAM-based Care
The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second randomization for the intervention group using a…
- Conditions
- Blood Pressure, Hypertension, Cancer, Cancer, Breast
- Trial name
- ONE TEAM (NCT04258813)
- Testing
- iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control
- Where
- United States
- Volunteers
- 313 people
- Sponsor
- Duke University
Ovarian Cancer
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.
- Trial name
- ORTRAI (NCT07361471)
- Testing
- molecular analysis
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Centre Jean Perrin
Ovarian Cancer, Ovarian Carcinoma
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovarian Cancer Stage IV, Ovarian Cancer Stage III
- Trial name
- NCT04997096
- Testing
- Exercise, Attention Control
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer, Mesothelioma
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
- Conditions
- Ovarian Cancer, Mesothelioma, Colon Cancer
- Trial name
- NCT07420010
- Testing
- KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)
- Volunteers
- 24 people
- Sponsor
- Weijia Fang, MD
Hereditary Breast and Ovarian Cancer
Cancer Genetics Hereditary Cancer Panel Testing
This study is about understanding the use of a genetic test (Myriad Genetics myRisk panel) that analyzes 25 genes related to different hereditary cancer conditions.
- Trial name
- HCP (NCT02324062)
- Testing
- Questionnaires, Blood Draw and Baseline Questionnaire
- Where
- 2 sites in United States
- Volunteers
- 1,511 people
- Sponsor
- University of Southern California
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Ovarian Mass
Concordance Between Radiologic Laparoscopic and Laparotomic Evaluation for Complete Cytoreduction of Ovarian Masses
Ovarian mass occur in women of all ages, and their etiology and frequency range age accordingly. The ovarian mass may come from functional or physiological changes, inflammatory processes, endometriosis, benign and malignant…
- Trial name
- NCT07416435
- Volunteers
- 28 people
- Sponsor
- Assiut University
Ovarian Cancer, Complication
Hysterectomy and OPPortunistic SAlpingectomy
HOPPSA is a register based randomized controlled trial (R-RCT), with the objective to examine if opportunistic salpingectomy compared with no salpingectomy, at the time of hysterectomy for a benign reason has no increased risk of…
- Trial name
- HOPPSA (NCT03045965)
- Testing
- Salpingectomy
- Where
- Sweden
- Volunteers
- 4,400 people
- Sponsor
- Göteborg University
Ovarian Neoplasm Epithelial, Homologous Recombination Deficiency
Functional Analysis of BRCAness
PARP inhibitors are most effective in homologous recombinant (HR) deficient tumors. There are clear indications that besides BRCA1 or BRCA2 mutated EOC, there is an additional group of EOC having deficiencies in HR (i.e.
- Conditions
- Ovarian Neoplasm Epithelial, Homologous Recombination Deficiency, BRCA1 Mutation, BRCA2 Mutation
- Trial name
- FAB (NCT04780945)
- Testing
- Functional RAD51 assay, Olaparib Oral Product
- Where
- 3 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Leiden University Medical Center
Ovarian Aging, IVF Outcome
The ROAR Study: Reactive Oxygen Species and Reproduction
This is a prospective cohort study characterizing follicular fluid and serum levels of oxidative stress in women with various infertility diagnoses undergoing in vitro fertilization, and assessing the relationship of oxidative…
- Conditions
- Ovarian Aging, IVF Outcome, Oxidative Stress
- Trial name
- ROAR (NCT06831019)
- Testing
- Oxidative stress markers
- Where
- United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Acute Leukemia, Multiple Myeloma
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk.
- Conditions
- Acute Leukemia, Multiple Myeloma, Squamous Cell Carcinoma, Pleural Mesothelioma
- Trial name
- IT-TCP POS (NCT07403630)
- Testing
- Functional tests, Multi-omics analyses, Cytogenetics/ FISH
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Epithelial Ovarian Cancer
Determining Prognostic Immune Markers in Patients With Ovarian Cancer
The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).
- Trial name
- IMPrOVE (NCT03862677)
- Testing
- No intervention
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Leiden University Medical Center
Advanced Solid Tumor, Ovarian Cancer
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
- Trial name
- NCT05103683
- Testing
- TORL-1-23
- Where
- 14 sites in United States, South Korea
- Volunteers
- 90 people
- Sponsor
- TORL Biotherapeutics, LLC
Ovarian Cancer
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)
Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)
- Trial name
- FOCUS / KOV-04 (NCT05827523)
- Testing
- Cisplatin
- Where
- 10 sites in South Korea
- Volunteers
- 520 people
- Sponsor
- National Cancer Center, Korea
Treatment Related Cancer, Ovarian Cancer
SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors
Single-arm, dose-increasing setting study of CAR macrophages in Mesothelin overexpressing solid tumors.
- Trial name
- NCT06562647
- Testing
- SY001
- Where
- 2 sites in China
- Volunteers
- 2 people
- Sponsor
- Cell Origin Biotech (Hangzhou) Co., Ltd.
Advanced Solid Tumor, Unresectable Solid Tumor
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
- Trial name
- GUARDIAN-101 (NCT06778863)
- Testing
- CLSP-1025
- Where
- 21 sites in United States
- Volunteers
- 90 people
- Sponsor
- Clasp Therapeutics, Inc.
Infertility (IVF Patients), Embryo Morphokinetics
IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols
The goal of this clinical trial is to compare two ovarian stimulation protocols used in in vitro fertilization (IVF): the fixed Progestin-Primed Ovarian Stimulation (PPOS) protocol and the GnRH Antagonist protocol.
- Conditions
- Infertility (IVF Patients), Embryo Morphokinetics, Progestins Primed Ovarian Stimulation
- Trial name
- NCT07409493
- Testing
- Progestin-Primed Ovarian Stimulation, Antagonist protocol for IVF
- Where
- Vietnam
- Volunteers
- 148 people
- Sponsor
- Hanoi Medical University
Ovarian Cancer Recurrent
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
This is a phase II single arm efficacy/safety trial that will evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP rintatolimod (TLR-3 agonist) and IV…
- Trial name
- NCT03734692
- Testing
- Rintatolimod, Pembrolizumab, Cisplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Robert Edwards